The European Medicines Agency has recommended for EU-wide approval 13 new medicines, including two orphans - Global Blood Therapeutics’ first-in-class therapy for sickle cell disease Oxbryta (voxelotor), and Pfizer/Opko Health’s treatment for growth hormone deficiency Ngenla (somatrogon).
The EMA has also recommended for pan-EU approval ObsEva’s Yselty (linzagolix choline), which the company says is a first-of-its-kind...